

ANI PHARMACEUTICALS INC  
Form 8-K  
February 20, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

---

Date of Report (Date of earliest event reported): **February 17, 2015**

**ANI PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

<b>Delaware</b> (State or other jurisdiction of incorporation)	<b>001-31812</b> (Commission File Number)	<b>58-2301143</b> (I.R.S. Employer Identification Number)
--	--	---

**210 Main Street West**

**56623**

**Baudette, Minnesota**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(218) 634-3500**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 17, 2015, upon recommendation of the Compensation Committee of the Board of Directors of ANI Pharmaceuticals, Inc. (the "Company"), the Company's Board of Directors approved performance bonus payments to the Company's executive officers, including the Company's named executive officers – Arthur S. Przybyl, Charlotte C. Arnold, Robert Schrepfer, and James G. Marken. The performance bonus payments to Mr. Przybyl, Ms. Arnold, Mr. Schrepfer and Mr. Marken are 90%, 60%, 60% and 45% of their respective 2014 base salary.

2

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ANI PHARMACEUTICALS, INC.**

By: /s/ Charlotte C. Arnold  
Charlotte C. Arnold  
*Vice President, Finance and Chief Financial Officer*

Dated: February 20, 2015